Navigation Links
Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
Date:9/18/2007

KNOXVILLE, Tenn.--Provectus Pharmaceuticals, Inc. (OTCBB: PVCT) announced preliminary results of its Phase 1 clinical trial of Provecta for the treatment of metastatic melanoma, the most aggressive form of skin cancer. Provecta demonstrated minimal side effects, significant efficacy and bystander effect on melanoma tumors in stage III patients. The study evaluated safety and efficacy of Provecta in a total of 20 subjects at two sites in Australia.

In the study, Provecta was injected once into one to twenty tumors in each subject. In addition to these treated tumors, an additional one to three tumors were left untreated in each subject to allow assessment of a potential "bystander effect" resulting from immune system response to tumor treatment. A total of 114 tumors were injected and 39 bystander tumors were observed in the study. Subjects were followed for 4 to 27 weeks. Study treatments were well tolerated and elicited minimal side effects, the most common being mild to moderate pain at the injection site.

Results for all evaluable tumors were tabulated using the RECIST (Response Evaluation Criteria in Solid Tumors) approach, which objectively grades response for each subject based on change in the sum of the longest diameter for each of the subject's tumors vs. baseline. Subject outcome was scored in terms of complete response (CR -- complete tumor disappearance or negative histopathology), partial response (PR -- 30% or more tumor shrinkage), stable disease (SD -- 29% shrinkage to 20% growth), and progressive disease (PD -- greater than 20% growth).

At final evaluation after injection with a single dose of Provecta, the following results were obtained: 20% of subjects achieved CR of their injected tumors, 20% achieved PR, 35% achieved SD and 25% achieved PD, corresponding to an objective response (CR+PR) in 40% of subjects and local disease control (CR+PR+SD) in 75% of subjects. Among those subjects achieving an objective response of their treated tumors, 25% achieved an objective response of their untreated bystander tumors, and 100% exhibited disease control in their bystander tumors. In contrast, for those subjects failing to achieve an objective response of their treated tumors, only 8% achieved an objective response of their bystander tumors, and 92% exhibited progressive disease in their bystander tumors. These differences in response of bystander lesions as a function of response of target lesions were statistically significant and support the occurrence of a bystander effect in subjects whose target lesions have been responsive to PV-10 chemoablation.

Craig Dees, Ph.D., Chief Executive Officer of Provectus stated, "While full analysis of our phase 1 data is yet to be completed and will be reported by other means, the significance of these top line numbers is compelling and serves to illustrate the unique properties of Provecta. Additionally, they reinforce the confidence level we've had since we first witnessed the effects of this drug for the treatment of melanoma. These results have motivated us to put forth an aggressive clinical plan designed to drive toward approval of Provecta for this devastating disease." Dees continued, "The response from the body's own immune system to those tumors that were left untreated makes our novel approach to treating the disease that much more attractive."


'/>"/>

Contact: Janet Vasquez
212-825-3210
Provectus Pharmaceuticals
Source:Eurekalert

Related medicine news :

1. Sweet corn releases antioxidants on cooking
2. An International Growth Standard For Childs Releases By WHO
3. The National Governors Association Releases Guidelines For Outbreak Of Bird Flu
4. Eli Lilly Releases Digital Insulin Pen
5. Experimental treatment for Ebola Virus Shows promising results in mice
6. Hormone Deficiency Results In Miscarriage
7. Gleevec gets hopeful results
8. Breast Implants May Interfere With The Interpretation Of Mammogram Results
9. DNA Testing For More Accurate Results
10. Operating on a Beating Heart Yields Better Results For Blocked Heart Arteries
11. IVF results may be affected by stress and other related factors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... Lewisville, TX (PRWEB) , ... June 25, 2016 , ... ... in the United States, named Dr. Sesan Ogunleye, as the Medical Director of its ... be the facility Medical Director of our new Mesquite location,” said Dr. James M. ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van Mitchell, ... at Work award to iHire in recognition of their exemplary accomplishments in worksite health ... annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. ...
(Date:6/24/2016)... ... 24, 2016 , ... Those who have experienced traumatic events may suffer from ... avenues, such as drug or alcohol abuse, as a coping mechanism. To avoid this ... coping following a traumatic event. , Trauma sufferers tend to feel a range of ...
(Date:6/24/2016)... ... June 24, 2016 , ... The ... in Dallas that it will receive two significant new grants to support its ... PHA marked its 25th anniversary by recognizing patients, medical professionals and scientists for ...
(Date:6/24/2016)... ... 2016 , ... Comfort Keepers® of San Diego, CA is excited to announce ... program to drive cancer patients to and from their cancer treatments. Comfort Keepers ... of life and ongoing independence. Getting to and from medical treatments is one ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016   Bay ... Rehabilitation Network,s Dean Center for Tick Borne ... Medicine and Rehabilitation, MIT Hacking Medicine, University of ... Innovation, today announced the five finalists of ... Lyme disease.  More than 100 scientists, clinicians, researchers, ...
(Date:6/24/2016)... June 24, 2016 Dehaier Medical Systems Ltd. ... which develops, markets and sells medical devices and wearable ... signed a strategic cooperation agreement with Hongyuan Supply Chain ... Chain") on June 20, 2016, to develop Dehaier,s new ... cooperation agreement, Dehaier will leverage Hongyuan Supply Chain,s sales ...
(Date:6/24/2016)...   Pulmatrix, Inc ., (NASDAQ: PULM ... announced today that it was added to the Russell ... comprehensive set of U.S. and global equity indexes on ... milestone for Pulmatrix," said Chief Executive Officer Robert ... progress in developing drugs for crucial unmet medical needs, ...
Breaking Medicine Technology: